Activation O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
contributes O
to O
development O
of O
doxorubicin B
- O
induced O
heart O
failure O
. O

Activation O
of O
the O
nuclear O
enzyme O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
by O
oxidant O
- O
mediated O
DNA O
damage O
is O
an O
important O
pathway O
of O
cell O
dysfunction O
and O
tissue O
injury O
in O
conditions O
associated O
with O
oxidative O
stress O
. O

Low B
- I
molecular I
- I
weight I
heparin I
for O
the O
treatment O
of O
patients O
with O
mechanical O
heart O
valves O
. O

Low B
- I
molecular I
- I
weight I
heparin I
( O
LMWH B
) O
offers O
theoretical O
advantages O
over O
UH B
, O
but O
is O
not O
currently O
considered O
in O
clinical O
guidelines O
as O
an O
alternative O
to O
UH B
in O
patients O
with O
prosthetic O
valves O
. O

All B
- I
trans I
- I
retinoic I
acid I
- O
induced O
erythema O
nodosum O
in O
patients O
with O
acute O
promyelocytic O
leukemia O
. O

Erythema O
nodosum O
associated O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
for O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
very O
rare O
. O

RESULTS O
: O
The O
3 O
patients O
had O
acute O
renal O
insufficiency O
, O
relative O
metabolic O
alkalosis O
, O
and O
low O
parathyroid O
hormone O
( O
PTH O
) O
, O
PTH O
- O
related O
peptide O
, O
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
concentrations O
. O

A O
Tween O
80 O
- O
coated O
poly B
- I
L I
- I
lactid I
acid I
nanoparticles O
was O
used O
as O
a O
model O
of O
colloidal O
drug O
delivery O
system O
, O
able O
to O
trespass O
the O
BBB O
. O

The O
toxic O
effects O
of O
tacrine B
- O
loaded O
poly B
- I
L I
- I
lactid I
acid I
nanoparticles O
( O
5mg O
/ O
kg O
) O
, O
a O
saline O
solution O
of O
tacrine B
( O
5mg O
/ O
kg O
) O
and O
an O
empty O
colloidal O
nanoparticle O
suspension O
were O
compared O
following O
i O
. O
p O
. O
administration O
in O
LiCl B
- O
pre O
- O
treated O
Wistar O
rats O
. O

In O
vivo O
characterization O
of O
a O
dual O
adenosine B
A2A I
/ I
A1 I
receptor I
antagonist I
in O
animal O
models O
of O
Parkinson O
' O
s O
disease O
. O

Morphine B
did O
not O
, O
however O
, O
alter O
the O
hyperalgesia O
induced O
by O
8 B
- I
bromo I
cyclic I
adenosine I
monophosphate I
. O

Tri B
- I
ortho I
- I
tolyl I
phosphate I
( O
TOTP B
) O
, O
360 O
mg O
/ O
kg O
, O
po O
, O
and O
0 B
, I
0 I
' I
- I
diisopropyl I
phosphorofluoridate I
( O
DFP B
) O
, O
1 O
mg O
/ O
kg O
sc O
, O
were O
administered O
to O
adult O
White O
Leghorn O
chickens O
24 O
hr O
after O
they O
were O
placed O
on O
diets O
containing O
0 O
to O
300 O
ppm O
corticosterone B
. O

Phase O
I O
trial O
of O
13 B
- I
cis I
- I
retinoic I
acid I
in O
children O
with O
neuroblastoma O
following O
bone O
marrow O
transplantation O
. O

PURPOSE O
: O
Treatment O
of O
neuroblastoma O
cell O
lines O
with O
13 B
- I
cis I
- I
retinoic I
acid I
( O
cis B
- I
RA I
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

Recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic B
acid I
amide I
, O
a O
selective O
inhibitor O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
; O
EC O
2 O
. O
4 O
. O
2 O
. O
30 O
) O
on O
mice O
suffering O
from O
acetaminophen B
( O
AAP B
) O
- O
hepatitis O
, O
suggesting O
that O
the O
AAP B
- O
induced O
liver O
injury O
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

5 B
, I
7 I
- I
dichlorokynurenic I
acid I
( O
5 B
, I
7 I
- I
DCKA I
) O
, O
a O
selective O
glycine B
site O
antagonist O
, O
injected O
in O
doses O
of O
2 O
. O
5 O
and O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol B
- O
induced O
muscle O
rigidity O
( O
MMG O
) O
and O
the O
enhanced O
electromyographic O
activity O
( O
EMG O
) O
. O

